Current gene therapy using viral vectors for chronic pain

Jean Marc G Guedon, Shaogen Wu, Xuexing Zheng, Caroline C. Churchill, Joseph C. Glorioso, Ching Hang Liu, Shue Liu, Lucy Vulchanova, Alex Bekker, Yuan Xiang Tao, Paul R. Kinchington, William F. Goins, Carolyn A. Fairbanks, Shuanglin Hao

Research output: Contribution to journalArticle

Abstract

The complexity of chronic pain and the challenges of pharmacotherapy highlight the importance of development of new approaches to pain management. Gene therapy approaches may be complementary to pharmacotherapy for several advantages. Gene therapy strategies may target specific chronic pain mechanisms in a tissue-specific manner. The present collection of articles features distinct gene therapy approaches targeting specific mechanisms identified as important in the specific pain conditions. Dr. Fairbanks group describes commonly used gene therapeutics (herpes simplex viral vector (HSV) and adeno-associated viral vector (AAV)), and addresses biodistribution and potential neurotoxicity in pre-clinical models of vector delivery. Dr. Tao group addresses that downregulation of a voltage-gated potassium channel (Kv1.2) contributes to the maintenance of neuropathic pain. Alleviation of chronic pain through restoring Kv1.2 expression in sensory neurons is presented in this review. Drs Goins and Kinchington group describes a strategy to use the replication defective HSV vector to deliver two different gene products (enkephalin and TNF soluble receptor) for the treatment of post-herpetic neuralgia. Dr. Hao group addresses the observation that the pro-inflammatory cytokines are an important shared mechanism underlying both neuropathic pain and the development of opioid analgesic tolerance and withdrawal. The use of gene therapy strategies to enhance expression of the anti-pro-inflammatory cytokines is summarized. Development of multiple gene therapy strategies may have the benefit of targeting specific pathologies associated with distinct chronic pain conditions (by Guest Editors, Drs. C. Fairbanks and S. Hao).

Original languageEnglish (US)
Article number27
JournalMolecular Pain
Volume11
Issue number1
DOIs
StatePublished - May 13 2015
Externally publishedYes

Fingerprint

Chronic Pain
Genetic Therapy
Neuralgia
Herpes Simplex
Cytokines
Voltage-Gated Potassium Channels
Drug Therapy
Enkephalins
Tumor Necrosis Factor Receptors
Sensory Receptor Cells
Pain Management
Opioid Analgesics
Genes
Anti-Inflammatory Agents
Down-Regulation
Maintenance
Pathology
Pain
Therapeutics

Keywords

  • Gene therapy
  • Pain
  • Viral vectors

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Molecular Medicine
  • Cellular and Molecular Neuroscience

Cite this

Guedon, J. M. G., Wu, S., Zheng, X., Churchill, C. C., Glorioso, J. C., Liu, C. H., ... Hao, S. (2015). Current gene therapy using viral vectors for chronic pain. Molecular Pain, 11(1), [27]. https://doi.org/10.1186/s12990-015-0018-1

Current gene therapy using viral vectors for chronic pain. / Guedon, Jean Marc G; Wu, Shaogen; Zheng, Xuexing; Churchill, Caroline C.; Glorioso, Joseph C.; Liu, Ching Hang; Liu, Shue; Vulchanova, Lucy; Bekker, Alex; Tao, Yuan Xiang; Kinchington, Paul R.; Goins, William F.; Fairbanks, Carolyn A.; Hao, Shuanglin.

In: Molecular Pain, Vol. 11, No. 1, 27, 13.05.2015.

Research output: Contribution to journalArticle

Guedon, JMG, Wu, S, Zheng, X, Churchill, CC, Glorioso, JC, Liu, CH, Liu, S, Vulchanova, L, Bekker, A, Tao, YX, Kinchington, PR, Goins, WF, Fairbanks, CA & Hao, S 2015, 'Current gene therapy using viral vectors for chronic pain', Molecular Pain, vol. 11, no. 1, 27. https://doi.org/10.1186/s12990-015-0018-1
Guedon JMG, Wu S, Zheng X, Churchill CC, Glorioso JC, Liu CH et al. Current gene therapy using viral vectors for chronic pain. Molecular Pain. 2015 May 13;11(1). 27. https://doi.org/10.1186/s12990-015-0018-1
Guedon, Jean Marc G ; Wu, Shaogen ; Zheng, Xuexing ; Churchill, Caroline C. ; Glorioso, Joseph C. ; Liu, Ching Hang ; Liu, Shue ; Vulchanova, Lucy ; Bekker, Alex ; Tao, Yuan Xiang ; Kinchington, Paul R. ; Goins, William F. ; Fairbanks, Carolyn A. ; Hao, Shuanglin. / Current gene therapy using viral vectors for chronic pain. In: Molecular Pain. 2015 ; Vol. 11, No. 1.
@article{dd984952a746430b81662ae12a5cefc8,
title = "Current gene therapy using viral vectors for chronic pain",
abstract = "The complexity of chronic pain and the challenges of pharmacotherapy highlight the importance of development of new approaches to pain management. Gene therapy approaches may be complementary to pharmacotherapy for several advantages. Gene therapy strategies may target specific chronic pain mechanisms in a tissue-specific manner. The present collection of articles features distinct gene therapy approaches targeting specific mechanisms identified as important in the specific pain conditions. Dr. Fairbanks group describes commonly used gene therapeutics (herpes simplex viral vector (HSV) and adeno-associated viral vector (AAV)), and addresses biodistribution and potential neurotoxicity in pre-clinical models of vector delivery. Dr. Tao group addresses that downregulation of a voltage-gated potassium channel (Kv1.2) contributes to the maintenance of neuropathic pain. Alleviation of chronic pain through restoring Kv1.2 expression in sensory neurons is presented in this review. Drs Goins and Kinchington group describes a strategy to use the replication defective HSV vector to deliver two different gene products (enkephalin and TNF soluble receptor) for the treatment of post-herpetic neuralgia. Dr. Hao group addresses the observation that the pro-inflammatory cytokines are an important shared mechanism underlying both neuropathic pain and the development of opioid analgesic tolerance and withdrawal. The use of gene therapy strategies to enhance expression of the anti-pro-inflammatory cytokines is summarized. Development of multiple gene therapy strategies may have the benefit of targeting specific pathologies associated with distinct chronic pain conditions (by Guest Editors, Drs. C. Fairbanks and S. Hao).",
keywords = "Gene therapy, Pain, Viral vectors",
author = "Guedon, {Jean Marc G} and Shaogen Wu and Xuexing Zheng and Churchill, {Caroline C.} and Glorioso, {Joseph C.} and Liu, {Ching Hang} and Shue Liu and Lucy Vulchanova and Alex Bekker and Tao, {Yuan Xiang} and Kinchington, {Paul R.} and Goins, {William F.} and Fairbanks, {Carolyn A.} and Shuanglin Hao",
year = "2015",
month = "5",
day = "13",
doi = "10.1186/s12990-015-0018-1",
language = "English (US)",
volume = "11",
journal = "Molecular Pain",
issn = "1744-8069",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Current gene therapy using viral vectors for chronic pain

AU - Guedon, Jean Marc G

AU - Wu, Shaogen

AU - Zheng, Xuexing

AU - Churchill, Caroline C.

AU - Glorioso, Joseph C.

AU - Liu, Ching Hang

AU - Liu, Shue

AU - Vulchanova, Lucy

AU - Bekker, Alex

AU - Tao, Yuan Xiang

AU - Kinchington, Paul R.

AU - Goins, William F.

AU - Fairbanks, Carolyn A.

AU - Hao, Shuanglin

PY - 2015/5/13

Y1 - 2015/5/13

N2 - The complexity of chronic pain and the challenges of pharmacotherapy highlight the importance of development of new approaches to pain management. Gene therapy approaches may be complementary to pharmacotherapy for several advantages. Gene therapy strategies may target specific chronic pain mechanisms in a tissue-specific manner. The present collection of articles features distinct gene therapy approaches targeting specific mechanisms identified as important in the specific pain conditions. Dr. Fairbanks group describes commonly used gene therapeutics (herpes simplex viral vector (HSV) and adeno-associated viral vector (AAV)), and addresses biodistribution and potential neurotoxicity in pre-clinical models of vector delivery. Dr. Tao group addresses that downregulation of a voltage-gated potassium channel (Kv1.2) contributes to the maintenance of neuropathic pain. Alleviation of chronic pain through restoring Kv1.2 expression in sensory neurons is presented in this review. Drs Goins and Kinchington group describes a strategy to use the replication defective HSV vector to deliver two different gene products (enkephalin and TNF soluble receptor) for the treatment of post-herpetic neuralgia. Dr. Hao group addresses the observation that the pro-inflammatory cytokines are an important shared mechanism underlying both neuropathic pain and the development of opioid analgesic tolerance and withdrawal. The use of gene therapy strategies to enhance expression of the anti-pro-inflammatory cytokines is summarized. Development of multiple gene therapy strategies may have the benefit of targeting specific pathologies associated with distinct chronic pain conditions (by Guest Editors, Drs. C. Fairbanks and S. Hao).

AB - The complexity of chronic pain and the challenges of pharmacotherapy highlight the importance of development of new approaches to pain management. Gene therapy approaches may be complementary to pharmacotherapy for several advantages. Gene therapy strategies may target specific chronic pain mechanisms in a tissue-specific manner. The present collection of articles features distinct gene therapy approaches targeting specific mechanisms identified as important in the specific pain conditions. Dr. Fairbanks group describes commonly used gene therapeutics (herpes simplex viral vector (HSV) and adeno-associated viral vector (AAV)), and addresses biodistribution and potential neurotoxicity in pre-clinical models of vector delivery. Dr. Tao group addresses that downregulation of a voltage-gated potassium channel (Kv1.2) contributes to the maintenance of neuropathic pain. Alleviation of chronic pain through restoring Kv1.2 expression in sensory neurons is presented in this review. Drs Goins and Kinchington group describes a strategy to use the replication defective HSV vector to deliver two different gene products (enkephalin and TNF soluble receptor) for the treatment of post-herpetic neuralgia. Dr. Hao group addresses the observation that the pro-inflammatory cytokines are an important shared mechanism underlying both neuropathic pain and the development of opioid analgesic tolerance and withdrawal. The use of gene therapy strategies to enhance expression of the anti-pro-inflammatory cytokines is summarized. Development of multiple gene therapy strategies may have the benefit of targeting specific pathologies associated with distinct chronic pain conditions (by Guest Editors, Drs. C. Fairbanks and S. Hao).

KW - Gene therapy

KW - Pain

KW - Viral vectors

UR - http://www.scopus.com/inward/record.url?scp=84930206269&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930206269&partnerID=8YFLogxK

U2 - 10.1186/s12990-015-0018-1

DO - 10.1186/s12990-015-0018-1

M3 - Article

C2 - 25517376

AN - SCOPUS:84930206269

VL - 11

JO - Molecular Pain

JF - Molecular Pain

SN - 1744-8069

IS - 1

M1 - 27

ER -